Aseptuva secures support to make its product market-ready

Aseptuva’s vision is to prevent Hospital Acquired Infections (HAI) and transform intensive care medicine globally with an innovation is built on optomechanical technologies. HAI, affecting over 4.4M patients across Europe every year, leads to 40’000 deaths. A major cause of HAI is bacterial colonization of surfaces on and around catheters, their subsequent entry through the skin-perforation site triggering lethal bloodstream infections. “Aseptuva’s innovation offers a promising solution to several overarching health challenges in the hospital infection control sector. The foreseeable direct impacts are healthcare cost savings, shortening of wait-time for in-patient services, reducing burden on healthcare workers, combat antimicrobial resistance”, conveys Henry Twerenbold, CEO Aseptuva.

The purpose of MedPhab is to accelerate the commercialisation of diagnostic devices and instruments for treatment based on photonics, and to reduce the R&D cost.. Within the scope of the project, Aseptuva will collaborate with MedPhab partners – Philips Innovation Partners and Tyndall, to scale-up from their product development activities up to a near market-ready device taking into consideration advanced manufacturing methods with quality assurance and precision engineering. 

“We are eager to support Aseptuva bringing their product to market.” says Simon Sorensen, Senior Researcher Tyndall. Willem-Jan de Wijs, Senior Architect, Philips Innovation Services adds: “MedPhab demonstrates the effectiveness of European cooperation between Research Technology Organisations, SMEs, and industry leaders across international borders. Thus, the collaboration provides essential resources to Aseptuva accelerating their product development.” The project recently started and will go until Mid-2024.

This project involves handling and development of state-of-the-art technologies in the field of photonics, microbiology, regenerative tissue engineering, which will immensely benefit the Aseptuva team to improve skills and acquire new knowledge within such a highly interdisciplinary project. Furthermore, the European fund convinced new investors and existing shareholders to be part of the recent launched seed round. “The MedPhab support is a boost. We are talking currently with further investors that help us closing the round”, explains Henry Twerenbold.

(Press release / SK)